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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYHematopoietic stem cells (HSCs) maintain blood homeostasis and are the functional units of bone marrow transplantation. To improve
the molecular understanding of HSCs and their proximal progenitors, we performed transcriptome analysis within the context of the
ImmGenConsortium data set. Gene sets that define steady-state andmobilized HSCs, as well as hematopoietic stem and progenitor cells
(HSPCs), were determined. Genes involved in transcriptional regulation, including a group of putative transcriptional repressors, were
identified in multipotent progenitors and HSCs. Proximal promoter analyses combined with ImmGenmodule analysis identified candi-
date regulators of HSCs. Enforced expression of one predicted regulator,Hlf, in diverse HSPC subsets led to extensive self-renewal activity
ex vivo. These analyses reveal unique insights into the mechanisms that control the core properties of HSPCs.INTRODUCTION
Hematopoietic stem cells (HSCs) reside at the apex of the
hematopoietic hierarchy and generate the entire reper-
toire of highly specialized hematopoietic effector cells by
differentiating through a succession of increasingly
committed progenitors. HSCs are the only hematopoietic
cell type that can differentiate into all blood lineages and
self-renew for life. These properties, along with HSCs’
remarkable ability to engraft conditioned recipients
upon intravenous transplantation, have established the
clinical paradigm for the application of stem cells in
regenerative medicine. Indeed, HSC transplantation is
routinely used to treat a variety of hematological condi-
tions, including leukemia, multiple myeloma, severe com-
bined immunodeficiency, and myelodysplastic syndrome.
Nonetheless, HSC transplantation remains a relative high-
risk procedure, with the most significant factor contrib-
uting to the success of the procedure being the size of
the transplanted graft (Siena et al., 2000). Enormous
efforts have therefore been mounted to develop methods
for expanding HSCs ex vivo, although these efforts have
not yet translated to the clinic. A greater understanding
of the molecular mechanisms underlying HSC fate and266 Stem Cell Reports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 Thefunction will undoubtedly inform strategies for the thera-
peutic manipulation of these cells, and may also improve
our understanding of hematopoietic malignancies derived
from stem cells.
The ability to purify HSCs to near homogeneity opens
the door for their precise molecular characterization by
microarray analysis. This approach is particularly useful
for studying HSCs because it allows for the simulta-
neous, quantitative detection of entire transcriptomes
from these rare cells. Although prior microarray studies
have provided useful insights into HSC biology (Cham-
bers et al., 2007; Forsberg et al., 2005, 2010; Rossi
et al., 2005), it has proved challenging to cross-analyze
data due to differences in experimental designs and
technical methodologies. The ImmGen Project over-
comes many of these limitations by generating transcrip-
tome data from stem cells, defined progenitors, and
various effector cells, using unified protocols of cell sort-
ing, RNA extraction, unamplified sample preparation,
and a common facility for microarray processing (Heng
and Painter, 2008; Painter et al., 2011). Additional
advantages of the ImmGen approach include a wider
breadth of assayed hematopoietic cell types and states
(250), increased statistical power through array numberAuthors
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Figure 1. Population Distances Define HSPCs in Transcriptional Space
(A) Population-distance analysis of microarray data presented in three principal components (PCs 1–3). Each point represents a single
array. Cell types are color-coded. B, B cells; DC, dendritic cells; GN, granulocytes; MF, macrophages; Mo, monocytes; NK, NK cells; NKT, NKT
cells; preT, T cell precursors; proB, B cell precursors; T, T cells; Tgd, gd T cells.
(B) Population-distance analysis of HSPC subsets including HSCs, MPPs (MPP1 and MPP2), and oligopotent progenitors (CLP, CMP, MEP,
and GMP).
See also Figure S1.
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Transcriptome Analysis of HSPCs(700 total), and utilization of the Affymetrix GeneChip
Mouse Gene ST 1.0 microarray platform, which includes
probes for >24,500 coding and >1,300 noncoding
transcripts.
Here, we used the breadth of the ImmGen data set to
delineate genes and regulators of the primitive hematopoi-
etic cells, bringing to light conceptual advances at three
levels of resolution: (1) hematopoietic stem and progenitor
cells (HSPCs), (2) multipotent stem and progenitor cells,
and (3) HSCs. All HSPCs showed enriched expression
of metabolic growth- and proliferation-associated genes,
which paradoxically were also expressed in quiescent
HSCs. Genes encoding transcription factors, including a
group of Kruppel-associated box (KRAB) domain-contain-
ing CH3 zinc-finger proteins that are predicted to function
as transcriptional repressors, were enriched in multipotent
progenitors (MPPs) and HSCs. Exposure to clinically rele-
vant mobilizing stimuli led to alterations in the expression
of HSPC regulators, as well as membrane and extracellular
matrix proteins and proteases. Proximal promoter analysis
of genes identified in steady-state HSPCs and mobilized
HSPCs (moHSPCs) revealed enrichment of motifs repre-
senting putative binding sites for both known and un-
known stem cell regulators, and ImmGen module analysis
of HSC-enriched genes independently identified potential
regulators. Enforced expression of one putative regulator,
Hlf, resulted in robust inductionof aprimitive immunophe-
notype, sustained colony-formation activity, and enhanced
self-renewal in a number of progenitor subsets ex vivo.Stem Cell RRESULTS
Comparative Transcriptional Distances between
Primitive HSPCs
The generation of effector blood cells from HSCs proceeds
through a series of downstream progenitors with increas-
ingly restricted potential (Bryder et al., 2006). The most
proximal progenitors to HSCs are MPPs, which retain full
lineage potential but lack long-term self-renewal potential.
As MPPs differentiate, they give rise to oligopotent progen-
itors of either lymphoid or myeloid effector cells. To
generate transcriptome data from primitive subsets, we
sorted HSCs, MPPs (MPP1 and MPP2), and oligopotent
progenitors (commonmyeloid progenitor [CMP], granulo-
cyte-macrophage progenitor [GMP], megakaryocyte-
erythroid progenitor [MEP], and common lymphoid pro-
genitor [CLP]) to a high degree of purity (for sorting details,
see Table S1 available online and http://www.immgen.org/
index_content.html) and subjected them to ImmGen
expression profiling and quality-control pipelines (Heng
and Painter, 2008). Hereafter, we refer collectively to these
primitive subsets as HSPCs. Principal component analysis
(PCA) was performed on the 20% most variable genes be-
tween HSPCs and their downstream progeny (Figure 1A).
Strikingly, all HSPC subsets clustered closely together in
relation to their downstream progeny, indicating that
hematopoietic progenitors as functionally diverse as
HSCs, CLPs, and CMPs share gene expression properties
that commonly define them in transcriptional space.eports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 The Authors 267
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Figure 2. HSPCs Are Enriched for Gene Sets that Enable Transit Amplification
(A) Reduced representation of hematopoiesis showing normalized and averaged values of 1,605 HSPC-enriched genes.
(B) DAVID analysis showing enriched categories, with adjusted p value (Benjamini).
(legend continued on next page)
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Transcriptome Analysis of HSPCsWe next interrogated the transcriptional relationships
among hematopoietic progenitors by performing PCA
analysis using the 20% most variable genes between the
HSPC subsets to define transcriptional distances. In agree-
ment with established functional relationships (Bryder
et al., 2006), MPP1 were positioned most proximal to
HSCs, followed by MPP2, whereas oligopotent lymphoid
and myeloid progenitors radiated farther along the prin-
cipal components (Figure 1B).HSPCs Are Transcriptionally Enriched for Genes
Associated with Transit Amplification
ThoughHSPCs represent a group of progenitors with diver-
gent functional attributes, the relatedness of their tran-
scriptomes (Figure 1A) prompted us to determine whether
we could identify a set of genes commonly expressed across
diverse HSPC subsets.We therefore analyzed the combined
HSPC subsets in comparison with their downstream
hematopoietic progeny by one-way ANOVA (false discov-
ery rate [FDR] < 5%, p < 1 3 105) and identified 1,605
genes with enriched expression in HSPCs (Figure S1A;
Table S2). A reduced representation of relative expression,
averaged from all 1,605 genes, showed high expression
in HSCs, MPPs, and oligopotent myeloid progenitors,
and a lower level of induction within CLPs (Figure 2A).
We next tested for functional enrichment in the Database
for Annotation, Visualization and Integrated Discovery
(DAVID)bioinformatics resource (http://david.abcc.ncifcrf.
gov/), which revealed significant enrichment for genes
associated with metabolic growth (ncRNA-metabolic,
tRNA-metabolic, and Ribosomal subunits) and prolifera-
tion (cell cycle, DNA-metabolic, and M-phase; Fisher’s
exact test, FDR < 4 3 104; Figure 2B), consistent with
the high cycling activity and transit amplification potential
of these progenitors.
To visualize the relative expression of genes identified by
ANOVA across the ImmGen data set, we normalized the
expression values of the genes in either the ncRNA meta-
bolic or cell cycle groups and plotted the average expres-
sion for each cell type (Figure 2C). This analysis showed
that in addition to HSPCs, these gene sets are also highly
expressed in early B and T cell progenitors (Figure 2C; Fig-
ures S1B and S1C), in line with the proliferative potential
of these precursors (Carpenter and Bosselut, 2010). In
contrast, effector cells such as granulocytes, dendritic cells,
and natural killer (NK) cells showedmarkedly lower expres-
sion, consistent with their terminally differentiated state.(C) Normalized and averaged values for the indicated categories acro
(D) Normalized and averaged values for the indicated categories in I
(E) Heatmap of positive and negative regulators of cell cycle in the i
See also Figure S2.
Stem Cell RInterestingly, HSCs showed relatively high expression of
metabolic growth and proliferation gene sets (Figure 2C),
despite the fact that they are largely quiescent in adults
(Bowie et al., 2006; Rossi et al., 2007; Wilson et al., 2008).
To further explore this apparent paradox, we plotted the
relative expression of genes in the ncRNA-metabolic, cell
cycle, and DNA-metabolic categories in a limited subset
of cell types, reasoning that this might allow us to discrim-
inate between genes that encompass both positive and
negative regulators of cell proliferation (found in the cell
cycle gene sets) and genes that are more tightly linked to
DNA synthesis (found in the DNAmetabolic gene sets; Fig-
ure 2D). Surprisingly, although the HSCs showed a slight
relative decrease in expression of genes associated with
DNA metabolism in comparison with other HSPC subsets,
they nonetheless exhibited relatively high expression of
genes in these categories. These data raise the possibility
that even though they reside predominantly in the quies-
cent G0 phase of the cell cycle, HSCs are nonetheless tran-
scriptionally poised to enter the cell cycle by expression of
genes that mediate cell-cycle progression. This postulate
implies that activemaintenance of quiescence is a requisite
feature of adult HSCs, a notion that has been borne out in
studies that have defined regulators that hold HSCs in a
quiescent state. To explore this concept further, we exam-
ined the expression of a subset of positive and negative reg-
ulators of the cell cycle (Figure 2E). Interestingly, whereas
HSCs clearly showed robust expression levels of cell-cycle
drivers such as Cdk2, Cdk4, and Cdk6, the only canonical
Cdk inhibitor with high expression in HSCs was Cdkn1c,
which encodes p57, a protein that was recently shown to
regulate HSC quiescence (Matsumoto et al., 2011; Zou
et al., 2011). The Rb family members also showed expres-
sion (albeit nonpreferential) in HSCs (Figure 2E), in
agreement with their combined role in regulating HSC
quiescence (Viatour et al., 2008).
Cumulatively, these results demonstrate that HSPCs
exhibit elevated expression of genes consistent with their
high cycling activity, and suggest that HSC quiescence is
a poised state in which genes and pathways required for
cell-cycle entry and growth are expressed.Identification of a Group of CH3 Zinc-Finger KRAB
Domain-Containing Transcriptional Repressors in
Multipotent Stem and Progenitor Cells
To identify genes and pathways enriched in hematopoietic
multipotency, we analyzed multipotent stem/progenitorsss the ImmGen data set. Cell types were grouped as indicated.
mmGen data sets.
ndicated cell types.
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AC
B
Figure 3. Hematopoietic Multipotent Stem and Progenitor Cells Express a Family of KRAB Domain-Containing Zinc-Finger Tran-
scriptional Repressors
(A) Reduced representation of hematopoiesis showing normalized and averaged values of 433 MPP-enriched genes.
(B) DAVID analysis showing enriched categories, with adjusted p value (Benjamini).
(C) Graphs showing the linear values (averaged array replicates ± SEM) of the indicated genes along differentiation trajectories from HSC
to MEP (green), GMP (red), PreB (purple), and PreT (blue). Biological replicates: n = 2 (MPP1, MPP2, and MEP), n = 3 (HSC, CMP, GMP, PreB,
and PreT), and n = 4 (CLP).
See also Figure S3.
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Transcriptome Analysis of HSPCs(HSCs, MPP1, and MPP2) as a group in comparison with
their downstream progeny, and identified 443 genes
with enriched expression (one-way ANOVA, FDR < 5%,
p < 1 3 104; Table S3; Figure S2). Reduced representation
of expression showed the highest relative expression in
HSCs, followed by MPP1s and MPP2s (Figure 3A). DAVID
analysis revealed a significant overrepresentation of
genes encoding KRAB domain-containing proteins and
C2H2 zinc-finger domain-containing proteins (Figure 3B).
When present in proteins that also contain DNA-binding
domains, KRAB domains canonically function to recruit
transcriptional repressors (Urrutia, 2003), and since all
of the KRAB domain-containing proteins we identified
also contain C2H2 zinc-finger DNA-binding domains, it270 Stem Cell Reports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 Theis predicted that these proteins function as transcriptional
repressors. To visualize their expression at increased
resolution, we focused our analysis on how their expres-
sion levels change during differentiation between stem
cell and defined downstream progenitor cell populations
(Figure 3C; Figure S3). The preferential expression of
these putative transcriptional repressors in primitive
progenitors that possess multilineage differentiation
capacity raises the possibility that they may be involved
in maintaining hematopoietic multipotency through
KRAB-mediated suppression of lineage commitment
pathways in a general (e.g., Zfp826 and Zfp12) or line-
age-specific (e.g., Gm14420, A630089N07Rik, Zkscan1,
and Zfp266) manner.Authors
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Transcriptome Analysis of HSPCsTranscriptional Regulation of HSCs
We next sought to identify genes and pathways that
might uniquely regulate HSCs within the hematopoietic
system. To achieve this, we compared the transcriptome
of HSCs with all other hematopoietic cell types in the
ImmGen data set and identified 322 genes with enriched
expression in HSCs (one-way ANOVA, FDR < 5%; Figures
4A and 4B; Table S4). Functional annotation by DAVID
showed that most genes could be grouped into a limited
number of categories, whereas 43% (138/322) of the iden-
tified HSC genes remained uncharacterized in any cell
type (Figure 4B). The 322 HSC-enriched genes were signif-
icantly enriched for KRAB domain-containing proteins
and C2H2 zinc-finger transcription factors, as observed
in the broader multipotent stem and progenitor cell
analysis. In total, 51 of the 322 HSC-enriched genes
were identified as transcription regulators (Figure 4C)
whose HSC-enriched expression proved to be conserved
between mouse and human (Figure 4D), and included
known HSC regulators such as Meis1, Mecom/Evi-1, Ndn,
MycN, and HoxA9 (Figures 4C and 4D). To explore the
interrelationships of these factors, we constructed a
functional gene network using a context likelihood of
relatedness (CLR)-based method (Faith et al., 2007) and
the entire ImmGen data set to derive connections be-
tween genes in this network representing nonrandom
and statistically significant dependencies. Strikingly, of
the 51 HSC-enriched transcription factors we identified,
48 segregated into two distinct clusters (Figure 4E). Inter-
estingly, all factors that were previously reported to oper-
ate functionally in HSCs fell into one network cluster,
suggesting that these genes may be under a common reg-
ulatory architecture (Figure 4E).
To clarify regulators of HSC-specific gene expression, we
next used de novo motif discovery (MEME) (Machanick
and Bailey, 2011) to analyze the proximal promoters of
the 322 HSC-enriched genes, defined as ±1,000 bp from
the transcription start sites (TSSs). We identified four
motifs, which TOMTOM analysis recognized as putative
binding sites of a number of transcription factors (Fig-
ure 4F). The most significant motif is a putative binding
site of EGR1, which was previously demonstrated to regu-
late HSC quiescence and retention in bone marrow (BM)
(Min et al., 2008). The second motif is a predicted binding
site for SOX4, which is reported to enhance murine HSC
reconstitution potential (Deneault et al., 2009). The third
motif is a predicted binding site for aryl hydrocarbon recep-
tor (AHR), which is striking in light of a recent report
demonstrating ex vivo expansion of HSCs using a purine
derivative that acts as an AHR agonist (Boitano et al.,
2010). The fourth motif is predicted to bind STAT1, which
is required for interferon-induced activation of HSCs (Ess-
ers et al., 2009).Stem Cell RTo further explore the potential regulatory network of
HSCs, we utilized module analysis (http://www.immgen.
org/ModsRegs/modules.html), which identifies putative
transcriptional regulators based on coexpression across
the ImmGen data sets. This analysis was undertaken with
the broader ImmGen data set that also includes nonhema-
topoietic cell types (e.g., stromal and endothelial cells).
Four modules were significantly enriched for the HSC-
induced genes (hypergeometric, p < 0.001; Figure 5A),
and each showed a pattern of high expression in stem cells
and downregulation upon hematopoietic differentiation.
Interestingly, the most enrichedmodule (#40) also showed
relatively high expression of a subset of HSC genes in endo-
thelial cells (Figure 5B; Figure S4A). This unexpected
finding may reflect the developmental origin of HSCs,
which are derived from a population of fetal hemogenic
endothelial cells (Dzierzak and Speck, 2008). The module
analysis also predicted 32 regulators for the four HSC-en-
riched modules (Figure 5C; Figure S4B) and included
STAT1 and SOX4, which we had identified based on en-
riched sequence motifs (Figure 4F). Some of the predicted
regulators (e.g., HoxA9 and Mecom) showed restricted
expression to the primitive hematopoietic compartment,
whereas others showed broader expression. The latter
group included established HSC regulators, such as Gata2,
MycN, and Erg, that showed high expression not only in
HSCs but also in endothelial cells (Figure 5C), consistent
with their established functional roles in both cell types
(Go¨ttgens et al., 2002; Linnemann et al., 2011; Ng et al.,
2011; Sato, 2001). Interestingly, the four enriched tran-
scription factor binding motifs we identified in HSCs (Fig-
ure 4F) are predicted to bind factors that are expressed in
both HSCs and endothelial cells (Egr1, Sox4, Ahr, and
Stat1), suggesting a shared regulatory program.
G-CSF Mobilization Induces Common Transcriptional
Changes in HSCs and MPPs
In adult mice and humans, a small percentage of HSCs and
progenitor cells migrate periodically from the BM niche
into the circulation (Massberg et al., 2007; Min et al.,
2008; Wright et al., 2001b). The frequency of HSCs in
the circulation increases significantly in response to
inflammation and following administration of mobilizing
agents. In particular, treatment of mice or humans
with a combination of cyclophosphamide/granulocyte col-
ony-stimulating factor (G-CSF; Cy/G) drives rapid prolifer-
ation, expansion, and migration of HSPCs from the BM to
peripheral hematopoietic compartments (Morrison et al.,
1997; Neben et al., 1993; Passegue´ et al., 2005), and mobi-
lization is routinely used in clinical practice to collect cells
for transplantation. However, themolecular regulators that
control HSC expansion and migration during this process
remain elusive.eports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 The Authors 271
A B
C
D
E
F
Figure 4. Identification of HSC-Specific Transcriptional Regulators
(A) Reduced representation of hematopoiesis showing normalized and averaged values of 322 HSC-enriched genes.
(B) Heatmap of all HSC-enriched genes across hematopoiesis. Functional classification as determined by DAVID.
(C) Expression of transcriptional regulators enriched (>4-fold) in murine HSCs presented as a ratio of mean expression in HSCs over the
mean expression in all other ImmGen cell types.
(D) Expression of the orthologs in (C) in human HSCs (Novershtern et al., 2011).
(legend continued on next page)
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Figure 5. ImmGen Module Analysis Identifies Putative Regulators of HSCs
(A) Graph showing modules (identifier numbers) significantly enriched with HSC-specific genes. Number of common genes and hyper-
geometric p values are indicated.
(B) Heatmap showing the averaged normalized expression of HSC genes in module #40.
(C) Absolute expression of HSC regulators predicted by ImmGen module analysis. Log2 values are shown.
See also Figure S4.
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Transcriptome Analysis of HSPCsHSCSlam andMPPSlam subsets were harvested from Cy/G-
treated mice (referred to hereafter as moHSCSlam and
moMPPSlam, respectively; Figure 6A), and RNA harvested
from these cells was compared with RNA extracted from
steady-state HSCSlam and MPPSlam (Table S1). Notably, the
cell purification strategy used for these mobilization ana-
lyses was different from the one used in the previous ana-
lyses (Figures 1, 2, 3, 4, and 5), due to the availability of ex-(E) Connectivity map based on correlated expression showing the 5
regulators of HSCs highlighted in orange. TF1 = 2810021G02Rik, TF2
(F) Significantly enriched sequence motifs ± 1,000 bp of TSS in HSC-e
binding factors.
Stem Cell Risting functional data that validated these marker sets for
isolation of the relevant cell populations from mobilized
mice. These samples were also processed with an amplifica-
tion step and therefore were analyzed separately from the
broad ImmGen data set. Importantly, despite the differ-
ences in immunophenotype, multiparameter fluores-
cence-activated cell sorting analyses andmean class expres-
sion analyses revealed that SLAM-code (Kiel et al., 2005)1 identified HSC-enriched transcriptional regulators, with known
= 2610008E11Rik, TF3 = A630033E08Rik, and TF4 = 10305D13Rik.
nriched genes, showing enrichment values (E values) and predicted
eports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 The Authors 273
Figure 6. MoHSPCs Express a Defined Gene Signature
(A) Schematic of the Cy/G treatment used to mobilize HSPCs. Mice were injected with a single dose of cyclophosphamide (Cy; 4 mg/mouse,
i.p.), followed by two daily G-CSF (G; 5 mg/mouse) injections (D2 Cy/G treatment). HSCSlam and MPPSlam were sorted from untreated and D2
Cy/G-treated mice for RNA extraction and microarray hybridization.
(B) Multiplot analysis to identify differentially expressed genes between each comparison (Hochberg test; FDR < 10%, fold change > 1.5).
(C) Heatmap of differentially expressed genes in moHSPC versus steady-state HSPC (FDR < 10%).
(D) Statistically significant transcription factor binding motifs (TFBs; in the upstream regulatory region and TSS [±1,000 bp]) of
differentially expressed genes. The putative TF family binding motif and the p value before the null model correction are noted.
(E) Table of the known upstream regulators of genes in the data set identified by the Ingenuity knowledge base (p < 0.05, right-tailed
Fisher’s exact test).
See also Figures S5 and S6.
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Transcriptome Analysis of HSPCsHSCs (LSKCD48-CD150+) showed significant overlap with
HSCs defined as LSKFlk2-CD34 (Figure S5A), and expres-
sion profiling revealed that the vast majority of genes are
similarly expressed in HSCs purified by either strategy
(Pearson correlation = 0.997; Figure S5B), with only 24
probe sets exhibiting significantly differential expression
(FDR < 10%, fold change > 2; Figure S5C). Moreover, PCA
of the 20% most variable genes across these populations
showed that HSCSlam and MPPSlam positioned closely to
the LKSCD34-Flk2 HSCs and MPP1s, respectively (Fig-
ure S5D), consistent with the previously ascribed immuno-
phenotypic and functional overlap of these populations
(Bryder et al., 2006).
Analysis of moHSPCs was performed at day 2 of the
mobilization protocol, the peak of Cy/G-induced HSC
expansion (Wright et al., 2001a, 2001b), when animals
typically show a 3- to 5-fold increase in HSPC number
(Forsberg et al., 2010; Passegue´ et al., 2005).We first consid-
ered in aggregate the expression patterns of steady-state
HSPCs and moHSPCs. This analysis revealed 15 genes
exhibiting differential expression (FDR < 10%) (Figure 6B
and 6C; Table S5), and of note was the upregulation in
extracellular and transmembrane proteases, including
Prtn3, which encodes a leukocyte serine protease (Protein-
ase 3) that degrades elastin, fibronectin, laminin, vitronec-
tin, and collagen IV, and has been suggested to act as a
‘‘path clearer’’ for neutrophil migration (Kuckleburg et al.,
2012). Although previous studies have implicated acti-
vated immune cells as the primary effectors of proteolysis
during HSPCmobilization, the upregulation of matrix pro-
teases in moHSPCs suggests that autocrine proteolysis may
also be important. To identify candidate transcriptional
regulators of the moHSPC genes, we performed MEME
analysis of proximal promoters (±1,000 bp of the TSS) of
the 15 moHSPC genes, which revealed two significantly
enriched motifs (Figure 6D). Ingenuity Pathway Analysis
(IPA) was used to identify an additional set of factors with
known binding sites (right-tailed Fisher’s exact test, p <
0.05; Figure 6E). To focus more specifically on the func-
tional effectors of BM transplant, we next examined our
data to identify genes that distinguish moHSCSlam and
moMPPSlam from their steady-state equivalents. Pairwise
analysis revealed 42 genes differentially expressed between
moHSCSlam and HSCSlam (fold change > 1.5; FDR < 10%;
Figure S6A; Table S6). This gene set was enriched for a num-
ber of functional categories, including apoptosis and cell
adhesion, exocytosis and actin cytoskeleton organization,
and cell motility (Figure S6C). Proximal promoter analysis
of the 42 moHSCSlam genes identified three enriched
sequencemotifs and corresponding regulators (Figure S6B).
In moMPPSlam, 182 genes were differentially expressed
(fold change > 1.5; FDR < 10%; Figure S6D; Table S7). IPA
revealed enrichment of a number of categories, includingStem Cell Rcell cycle and cancer and cell movement and immune
cell trafficking, among others (Figure S6F).
Altogether, the genes identified through this analysis
define a molecular signature associated with HSPC pro-
liferation and mobilization. Importantly, HSCSlam and
MPPSlam display remarkably similar transcription profiles
during mobilization, despite inherent differences in
their self-renewal potential, thereby suggesting common
targets in stem and progenitor cells whose manipula-
tion can lead to perturbed proliferation, adhesion, and
migration.
Hlf Is a Positive Regulator of Multilineage Potential
and Self-Renewal In Vitro
A central goal in our analysis of HSC-specific expression
patterns was to identify key regulators that modulate HSC
fate and function. We chose Hlf for functional validation
because it is one of the most strikingly HSC-specific genes
(Figures 4B–4D) and was predicted by module analysis to
be an HSC regulator (Figure 5C). Hlf encodes a PAR-bZIP
transcription factor that is studied principally in the
context of acute leukemia involving the t(17;19) transloca-
tion that generates the oncogenic E2A-HLF fusion protein
(Hunger et al., 1992; Inaba et al., 1992). Ectopic expression
of HLF was reported to enhance the short-term xenograft
potential of human lineage-negative cord blood cells, sug-
gesting an important role in HSPC biology (Shojaei et al.,
2005). We therefore constructed doxycycline-inducible
Hlf and control lentiviruses containing an IRES-ZsGreen
reporter cassette, and transduced HSCs, MPP1s, MPP2s,
CMPs, GMPs and MEPs purified from mice expressing
the reverse tet-transactivator, rtTA, at the Rosa26 locus
(Hochedlinger et al., 2005). Transduced cells were cultured
and immunostained at weekly intervals for lineagemarkers
and CD150 (Slamf1) to monitor differentiation and eval-
uate the presence of primitive hematopoietic progenitors.
Enforced expression of Hlf in HSCs caused a significant
percentage of cells to maintain a linCD150+ immunophe-
notype during 3 weeks of ex vivo culturing, whereas
control-transduced HSCs quickly lost this primitive
immunophenotype and became lin+CD150 (Figure 7A).
Strikingly, Hlfwas also able to induce a linCD150+ immu-
nophenotype in a number of downstream progenitors that
were initially sorted as CD150, which was maintained
over several weeks of culturing (Figure 7A). After 30 days
of culture in the presence of doxycycline, the Hlf-trans-
duced cultures contained multiple myeloid cell types,
including megakaryocytes, macrophages, granulocytes,
and undifferentiated cells, whereas the control cultures
contained only macrophages (Figure 7B). In an indepen-
dent experiment, ectopic expression of Hlf or HoxB4 in
HSCsmaintainedmixedmyeloid colony-forming potential
after long-term (45 days) ex vivo culturing. In contrast,eports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 The Authors 275
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Figure 7. HLF Is a Positive Regulator of Multipotency and Self-Renewal In Vitro
(A) Representative flow-cytometry plots showing CD11b and CD150 staining (left) and the time course (right) of the indicated HSPC
subsets transduced with control (ZsGreen) or HLF lentiviruses. Plots (left) were generated 2 weeks posttransduction in liquid culture. Cells
were pregated on lineage markers (CD3, B220, Ter119, and Gr1). Representative experiment with three biological replicates (±SEM). *p <
0.05.
(B) Cytospin showing representative cell types generated by HSCs transduced with control or HLF-expressing lentiviruses and maintained
in liquid culture for 30 days.
(C) Colony number and composition from HSCs transduced with control, HoxB4, or HLF-expressing lentiviruses and cultured for 45 days
prior to plating. Three biological replicates per sample (±SEM).
(D) Colony number and composition upon serial plating in methylcellulose of the indicated stem and progenitor cells transduced with
control or HLF-expressing lentiviruses. Three biological replicates per sample (±SEM).
See also Figure S7.
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colony-forming potential, and an inability to maintain of
mixed myeloid lineage potential. Thus, ectopic expression276 Stem Cell Reports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 Theof Hlf leads to the maintenance of mixed myeloid lineage
potential within HSC cultures even after prolonged
ex vivo culturing.Authors
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Transcriptome Analysis of HSPCsTo further examine the functional potential of Hlf,
we sorted and transduced HSCs, MPPs, and cKit
Sca1+lineage myeloid progenitors (MyPros) with Hlf or
control virus, and assayed for colony-forming cell (CFC) ac-
tivity in methylcellulose-based serial plating experiments.
Both control and Hlf-transduced cells produced colonies
in the primary plating, although Hlf-transduced MPPs
and MyPros generated significantly more colonies (Fig-
ure 7D). Secondary and tertiary plating revealed that only
Hlf-transduced cells continued to robustly generate col-
onies, whereas control-transduced cells lost activity, as ex-
pected. Importantly, quantification of colony types further
revealed that Hlf expression conferred sustained multiline-
age potential, as evidenced by the presence of CFU-GEMM
colonies at each plating (Figure 7D).Withdrawal of doxycy-
cline led to loss of CFC activity, indicating that continued
Hlf expression is necessary to sustain replating potential
(Figure S7). Taken together, these experiments demonstrate
that Hlf can impart potent, sustained self-renewal activity
on HSCs and downstream progenitors during ex vivo
manipulation.DISCUSSION
HSPCs include rapidly cycling progenitor cells that pro-
duce vast numbers of effector cells on a daily basis. It
was therefore not unexpected to find that genes involved
in cell cycle and metabolic growth were enriched in
HSPCs, but surprisingly, we also discovered that many of
these genes are highly expressed in quiescent HSCs.
Undoubtedly, this result is influenced in part by the fact
that certain aspects of cell-cycle regulation occur posttran-
scriptionally. Although it is possible that the small percent-
age (5%) of cycling HSCs (Passegue´ et al., 2005; Rossi
et al., 2007; Wilson et al., 2008; Yamazaki et al., 2006)
might account for all or most of the transcripts associated
with cell cycle and metabolic growth, this possibility is
unlikely to explain the high expression levels we observed.
Robust expression of cell-cycle progression and metabolic
growth genes in HSCs is consistent with the idea that,
despite quiescence, these cells are primed for rapid activa-
tion, possibly as a mechanism to allow for rapid cell-cycle
entry in response to acute injury or stress. Moreover, these
data suggest that the balance between HSC dormancy and
activation is regulated, at least in part, posttranscription-
ally. In support of this, p57, the CDK inhibitor that is
responsible for maintaining HSC quiescence (Matsumoto
et al., 2011; Zou et al., 2011), has been shown to localize
to the cytoplasm along with CyclinD2 in quiescent
HSCs, and upon cytokine stimulation p57 is rapidly
degraded concomitantly with translocation of CyclinD2
to the nucleus and entry into the cell cycle (Passegue´Stem Cell Ret al., 2005; Rossi et al., 2007;Wilson et al., 2008; Yamazaki
et al., 2006).
Delineating the transcriptional programs that underlie
HSPC cell mobilization provides molecular insight into
the regulation and function of cells whose robust activity
is essential for the clinical success of hematopoietic cell
transplantation. Retention of HSPCs within the stem cell
‘‘niche’’ is regulated in part by interactions between ligands
expressed in the niche and receptors on the surfaces of
HSPCs (such as SDF-1–CXCR4; TPO-MPL, and VLA-4–
VCAM-1). G-CSF treatment is thought to attenuate these
retention signals via stimulation of proteolytic enzymes
to promote HSPC egress from BM into the circulation
(Dar et al., 2006). Although activated myeloid cells are
widely acknowledged as a primary source for such proteo-
lytic enzymes, our analysis unexpectedly identified HSPC
intrinsic upregulation of several genes encoding extracel-
lular and transmembrane proteases, suggesting that HSPCs
may produce autocrine signals that promote their migra-
tion in response to mobilizing signals. Intriguingly, many
of the enriched moHSPC biological functions and molecu-
lar pathways mirror those used by immune and/or cancer
cells for attachment, migration, and homing (Tables S5,
S6, and S7). Further elucidation of these common path-
ways and the many as yet uncharacterized genes will
enhance our understanding of stem and progenitor cells
during mobilization, andmay potentially lead to increased
clinical efficacy of stem-cell-targeted therapies for hemato-
poietic malignancies.
Although several genes have been identified that regulate
HSC self-renewal and quiescence, candidate regulators of
hematopoietic multipotency remain elusive. Therefore,
our identification of a large family of mostly unstudied
KRAB domain-containing zinc-finger transcriptional regu-
lators whose expression is enriched within themultipotent
HSC compartment is intriguing. CH3 zinc-finger proteins
bind DNA with each finger interacting with three or four
bases (Urrutia, 2003). Because the genes we identified in
this family encode proteins that contain three to 23 zinc
fingers (average 12), they likely bind with great specificity
within the genome. Strikingly, because each of these fac-
tors also contain KRAB domains, which canonically func-
tion to recruit proteins to mediate transcriptional repres-
sion, the proteins we have identified are likely to act as
transcriptional repressors. Given their enriched expression
inmultipotent progenitors, we hypothesize that the collec-
tive activity of these factors may be involved in maintain-
ing hematopoietic multipotency, perhaps through active
repression of lineage commitment and differentiation pro-
grams. Interestingly, expression for most of these factors is
not fully restricted to the multipotent stem (HSC) and pro-
genitor (MPP) cell compartments, and instead is often
maintained in one or more downstream lineages. Sucheports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 The Authors 277
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individual factors function to repress commitment to
defined lineages and therefore must be maintained during
commitment to opposing lineages as a means of
preventing aberrant activation of gene programs associated
with other lineages. For example, expression of the
KRAB-containing zinc-finger genes Gm14420 and
A630089N07Rik is maintained from HSCs and MPPs
through toMEPs, but is significantly diminished in progen-
itors of other lineages, includingGMPs, pre-B cells, and pre-
T cells, suggesting that these two proteins may be involved
in repressing genes associated with non-MEP cell fates. The
hypothesis that these KRAB domain-containing regulators
play a role in maintaining multipotency in HSPCs through
suppression of differentiation pathways in either a general
or lineage-specific manner remains to be experimentally
tested.
The mechanisms that regulate the central properties of
HSCs are not fully understood. Using the vast resource of
ImmGen, we sought to identify genes with enriched
expression inHSCs, reasoning that such genesmight repre-
sent key regulators of stem cell fate and function. In
support of this, we readily identified several known HSC
regulators, including HoxB4, Erg, HoxA9, Meis1, Egr1, and
Mecom (Orkin and Zon, 2008), as well as genes that have
not previously been implicated in HSC biology. Based on
its HSC-specific expression and predicted regulatory role
as determined by module analysis, we identified Hlf as a
high-priority candidate for functional validation. We
found thatHlf endowedHSCs and downstreamprogenitors
with enhanced self-renewal, and sustained long-term
mixed myeloid lineage potential during ex vivo culturing.
Interestingly, these results complement and extend a previ-
ous report examining HLF-expression in human HSPCs, in
which ectopic expression of HLF led to an increase in the
short-term xenograft potential of human lineage-negative
cord blood cells containing HSCs and all of their down-
stream progenitor progeny (Shojaei et al., 2005). Our
finding that HLF can impart potent and sustained self-
renewal activity to HSPCs ex vivo suggests that increased
self-renewal of HSPCs may underlie the observations re-
ported by Shojaei et al. (2005).
The insights this study provides into the transcriptional
regulation of HSCs, combined with the identification of
HSC-specific transcription factors, could eventually lead
to the development of combinatorial strategies aimed at
inducing HSC potential in nonstem cells in a manner
similar to that used for the reprogramming of other cell
types (Graf and Enver, 2009). Moreover, our findings
regarding the transcriptional programs that regulate the
central properties of HSCs not only provide insights into
the basic biology of these cells but may also illuminate
innovative strategies to improve their clinical utility.278 Stem Cell Reports j Vol. 1 j 266–280 j September 10, 2013 j ª2013 TheEXPERIMENTAL PROCEDURES
Sorting HSPCs
Immunophenotypes of HSPC subsets are shown in Table S1. Cyto-
kine-induced mobilization of HSPCs was performed as previously
described (Passegue´ et al., 2005). Experimental cell-sorting and
processing schemes are available at https://www.immgen.org/
index_content.html.Microarray and Informatic Analysis
ImmGen V1 samples were not amplified prior to microarray
hybridization, except for those cells obtained in the mobilization
studies presented herein, which were amplified (Genisphere)
prior to hybridization. For this reason, these data sets were
normalized and analyzed independently of the broader ImmGen
data set. The numbers of microarrays utilized for stem and
progenitor cell populations are as follows: HSC (3), MPP1 (2),
MPP2 (2), CMP (3), MEP (2), GMP (3), CLP (4), pre-B cells (3),
and pre-T cells (3). In order to identify genes with enriched
expression in different hematopoietic subsets, one-way ANOVA
was implemented by the MATLAB function anova1. Secondary
analysis was implemented by the MATLAB function multi-
compare. Gene lists were subjected to standard enrichment
analysis through DAVID (Huang et al., 2009). For the mobilized
HSCSlam and MPPSlam comparisons, biological functions and
molecular pathway analysis association networks were generated
by IPA software (v8.7; Ingenuity Systems). Significance in the
data set analyzed by IPA was determined by a right-tailed Fisher’s
exact test (p < 0.05) using the whole IPA knowledge base as a
reference set. To generate heatmaps, Gct files of the selected genes
were visualized through GenePattern. Module analysis was done
as previously described (Jojic et al., 2013).Gene Network Prediction
A functional gene network was constructed using the full set of
ImmGen microarrays (March 2010 release). The gene-by-microar-
ray matrix of expression values was taken as input to the CLR
algorithm (Faith et al., 2007). Briefly, CLR calculates a mutual in-
formation matrix of all pairwise gene-by-gene expression profiles,
where an expression profile is defined as the vector of log2-trans-
formed expression values across all ImmGen cell populations.
For each individual gene, the distribution of mutual information
values is Z transformed to derive a normal distribution. Back-
ground correction for each gene is applied using Stouffer’s Z-score
method to combine Z scores. An FDR is calculated for each of these
values and an edge is drawn between two genes if the calculated
FDR < 1 3 103. Cytoscape was used for network visualization
(Shannon et al., 2003).Motif Analysis
Proximal Promoter sequences (±1,000 bp of TSS) were retrieved
from Ensemble BioMart (Kinsella et al., 2011) using the NCBI
v37 mouse genome assembly. MEME-chromatin immunoprecipi-
tation (MEME-ChIP) (Machanick and Bailey, 2011) was used to
identify enriched sequence motifs between 6 and 30 bp.Authors
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Hlf (MGI:96108) was cloned into the pHAGE2 lentivirus (Mosto-
slavsky et al., 2005) under a TRE promoter. Cells were double sorted
for purity and transduced at 100 multiplicity of infection. For
in vitro immunophenotype assays, cells were cultured in Dulbec-
co’s modified Eagle’s medium/F-12 media supplemented with
doxycycline (1 mg/ml), L-glutamine, pen-strep, nonessential
amino acids, beta-mercaptoethanol, 10% fetal bovine serum, and
the cytokines thrombopoietin, stem cell factor, interleukin-3,
and flt3L (each at 10 ng/ml). For CFC assays, cells were transduced,
and cultured in liquid media for 2 days, and then transduced cells
were sorted and plated inM3434methylcellulosemedia (StemCell
Technologies) at 250 cells per well. Colony number and type were
quantified on day 9 or 10, followed by serial replating of 10,000
cells per well.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and seven tables
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